An RNA profile identifies two subsets of multiple sclerosis patients differing in disease activity

Linda Ottoboni, Brendan T. Keenan, Pablo Tamayo, Manik Kuchroo, Jill P. Mesirov, Guy J. Buckle, Samia J. Khoury, David A. Hafler, Howard L. Weiner, Philip L. De Jager

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

The multiple sclerosis (MS) patient population is highly heterogeneous in terms of disease course and treatment response. We used a transcriptional profile generated from peripheral blood mononuclear cells to define the structure of an MS patient population. Two subsets of MS subjects (MS A and MSB) were found among 141 untreated subjects. We replicated this structure in two additional groups of MS subjects treated with one of the two first-line disease-modifying treatments in MS: glatiramer acetate (GA) (n = 94) and interferon-β (IFN-β) (n = 128). One of the two subsets of subjects (MSA) was distinguished by higher expression of molecules involved in lymphocyte signaling pathways. Further, subjects in this MSA subset were more likely to have a new inflammatory event while on treatment with either GA or IFN-β (P = 0.0077). We thus report a transcriptional signature that differentiates subjects with MS into two classes with different levels of disease activity.

Original languageEnglish
Article number153ra131
JournalScience Translational Medicine
Volume4
Issue number153
DOIs
Publication statusPublished - Sep 26 2012

Fingerprint

Multiple Sclerosis
RNA
Interferons
Population
Blood Cells
Therapeutics
Lymphocytes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Ottoboni, L., Keenan, B. T., Tamayo, P., Kuchroo, M., Mesirov, J. P., Buckle, G. J., ... De Jager, P. L. (2012). An RNA profile identifies two subsets of multiple sclerosis patients differing in disease activity. Science Translational Medicine, 4(153), [153ra131]. https://doi.org/10.1126/scitranslmed.3004186

An RNA profile identifies two subsets of multiple sclerosis patients differing in disease activity. / Ottoboni, Linda; Keenan, Brendan T.; Tamayo, Pablo; Kuchroo, Manik; Mesirov, Jill P.; Buckle, Guy J.; Khoury, Samia J.; Hafler, David A.; Weiner, Howard L.; De Jager, Philip L.

In: Science Translational Medicine, Vol. 4, No. 153, 153ra131, 26.09.2012.

Research output: Contribution to journalArticle

Ottoboni, L, Keenan, BT, Tamayo, P, Kuchroo, M, Mesirov, JP, Buckle, GJ, Khoury, SJ, Hafler, DA, Weiner, HL & De Jager, PL 2012, 'An RNA profile identifies two subsets of multiple sclerosis patients differing in disease activity', Science Translational Medicine, vol. 4, no. 153, 153ra131. https://doi.org/10.1126/scitranslmed.3004186
Ottoboni, Linda ; Keenan, Brendan T. ; Tamayo, Pablo ; Kuchroo, Manik ; Mesirov, Jill P. ; Buckle, Guy J. ; Khoury, Samia J. ; Hafler, David A. ; Weiner, Howard L. ; De Jager, Philip L. / An RNA profile identifies two subsets of multiple sclerosis patients differing in disease activity. In: Science Translational Medicine. 2012 ; Vol. 4, No. 153.
@article{016c64d0e56240128860d16bb1c03eea,
title = "An RNA profile identifies two subsets of multiple sclerosis patients differing in disease activity",
abstract = "The multiple sclerosis (MS) patient population is highly heterogeneous in terms of disease course and treatment response. We used a transcriptional profile generated from peripheral blood mononuclear cells to define the structure of an MS patient population. Two subsets of MS subjects (MS A and MSB) were found among 141 untreated subjects. We replicated this structure in two additional groups of MS subjects treated with one of the two first-line disease-modifying treatments in MS: glatiramer acetate (GA) (n = 94) and interferon-β (IFN-β) (n = 128). One of the two subsets of subjects (MSA) was distinguished by higher expression of molecules involved in lymphocyte signaling pathways. Further, subjects in this MSA subset were more likely to have a new inflammatory event while on treatment with either GA or IFN-β (P = 0.0077). We thus report a transcriptional signature that differentiates subjects with MS into two classes with different levels of disease activity.",
author = "Linda Ottoboni and Keenan, {Brendan T.} and Pablo Tamayo and Manik Kuchroo and Mesirov, {Jill P.} and Buckle, {Guy J.} and Khoury, {Samia J.} and Hafler, {David A.} and Weiner, {Howard L.} and {De Jager}, {Philip L.}",
year = "2012",
month = "9",
day = "26",
doi = "10.1126/scitranslmed.3004186",
language = "English",
volume = "4",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "153",

}

TY - JOUR

T1 - An RNA profile identifies two subsets of multiple sclerosis patients differing in disease activity

AU - Ottoboni, Linda

AU - Keenan, Brendan T.

AU - Tamayo, Pablo

AU - Kuchroo, Manik

AU - Mesirov, Jill P.

AU - Buckle, Guy J.

AU - Khoury, Samia J.

AU - Hafler, David A.

AU - Weiner, Howard L.

AU - De Jager, Philip L.

PY - 2012/9/26

Y1 - 2012/9/26

N2 - The multiple sclerosis (MS) patient population is highly heterogeneous in terms of disease course and treatment response. We used a transcriptional profile generated from peripheral blood mononuclear cells to define the structure of an MS patient population. Two subsets of MS subjects (MS A and MSB) were found among 141 untreated subjects. We replicated this structure in two additional groups of MS subjects treated with one of the two first-line disease-modifying treatments in MS: glatiramer acetate (GA) (n = 94) and interferon-β (IFN-β) (n = 128). One of the two subsets of subjects (MSA) was distinguished by higher expression of molecules involved in lymphocyte signaling pathways. Further, subjects in this MSA subset were more likely to have a new inflammatory event while on treatment with either GA or IFN-β (P = 0.0077). We thus report a transcriptional signature that differentiates subjects with MS into two classes with different levels of disease activity.

AB - The multiple sclerosis (MS) patient population is highly heterogeneous in terms of disease course and treatment response. We used a transcriptional profile generated from peripheral blood mononuclear cells to define the structure of an MS patient population. Two subsets of MS subjects (MS A and MSB) were found among 141 untreated subjects. We replicated this structure in two additional groups of MS subjects treated with one of the two first-line disease-modifying treatments in MS: glatiramer acetate (GA) (n = 94) and interferon-β (IFN-β) (n = 128). One of the two subsets of subjects (MSA) was distinguished by higher expression of molecules involved in lymphocyte signaling pathways. Further, subjects in this MSA subset were more likely to have a new inflammatory event while on treatment with either GA or IFN-β (P = 0.0077). We thus report a transcriptional signature that differentiates subjects with MS into two classes with different levels of disease activity.

UR - http://www.scopus.com/inward/record.url?scp=84866871850&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866871850&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.3004186

DO - 10.1126/scitranslmed.3004186

M3 - Article

C2 - 23019656

AN - SCOPUS:84866871850

VL - 4

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 153

M1 - 153ra131

ER -